Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Issued Date
2026-04-01
Resource Type
ISSN
01695002
eISSN
18728332
Scopus ID
2-s2.0-105030134618
Journal Title
Lung Cancer
Volume
214
Rights Holder(s)
SCOPUS
Bibliographic Citation
Lung Cancer Vol.214 (2026)
Suggested Citation
Hayashi H., Cho B.C., Kim Y.J., Lee S.H., Danchaivijitr P., Alip A., Xiong H., How S.H., Chang G.C., Yang J.C.H., Yamanaka Y., Nahit Şendur M.A., Prabhash K., Azuma K., Akawung A., Fennema E., Tang X., Shah S., Sethi S., Lu S. Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. Lung Cancer Vol.214 (2026). doi:10.1016/j.lungcan.2026.109305 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115291
Title
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis
Author's Affiliation
Universiti Malaya
National Taiwan University Hospital
Samsung Medical Center, Sungkyunkwan university
International Islamic University Malaysia
Seoul National University Bundang Hospital
Kurume University School of Medicine
Siriraj Hospital
Chung Shan Medical University Hospital
Kindai University School of Medicine
Tata Memorial Hospital
Ankara Yildirim Beyazit University
Johnson & Johnson
Shanghai Chest Hospital
Johnson & Johnson Pharmaceutical Research & Development, Raritan
Yonsei Cancer Hospital
Kansai Medical University Hospital
Huizhou Municipal Central Hospital of Guangdong Province
National Taiwan University Hospital
Samsung Medical Center, Sungkyunkwan university
International Islamic University Malaysia
Seoul National University Bundang Hospital
Kurume University School of Medicine
Siriraj Hospital
Chung Shan Medical University Hospital
Kindai University School of Medicine
Tata Memorial Hospital
Ankara Yildirim Beyazit University
Johnson & Johnson
Shanghai Chest Hospital
Johnson & Johnson Pharmaceutical Research & Development, Raritan
Yonsei Cancer Hospital
Kansai Medical University Hospital
Huizhou Municipal Central Hospital of Guangdong Province
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Approximately 60 % of lung cancer cases occur in Asia, indicating an epidemiological disparity and need for effective therapies. Amivantamab-lazertinib is approved for first-line EGFR-mutated advanced non-small cell lung cancer (NSCLC) in many countries. In the protocol-specified final overall survival (OS) analysis of MARIPOSA (NCT04487080), amivantamab-lazertinib showed a statistically significant and clinically meaningful improvement in OS versus osimertinib (HR, 0.75; P = 0.005) among all participants. We evaluated OS for amivantamab-lazertinib versus osimertinib in Asian participants. Patients and methods: Participants with previously untreated EGFR-mutated, locally advanced/metastatic NSCLC were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib, or lazertinib (for evaluating contribution of components). Self-identified Asian race was a stratification factor. OS was a key secondary endpoint. Results: Of 1074 randomized participants, 629 self-identified as Asian (amivantamab-lazertinib:250; osimertinib:251; lazertinib:128). At a median follow-up of 38.7 months, amivantamab-lazertinib significantly prolonged OS versus osimertinib among Asian participants. Median OS was not reached (NR; 95 % CI, NR–NR) for amivantamab-lazertinib versus 38.4 months (95 % CI, 35.1–NR) for osimertinib (HR, 0.74; 95 % CI, 0.56–0.97; nominal P = 0.026). Assuming exponential distribution of OS in both arms, amivantamab-lazertinib is projected to prolong median OS among Asian participants by > 12 months versus osimertinib. At 36 months, 61 % and 53 % were alive in the amivantamab-lazertinib and osimertinib arms. Safety profile was consistent with the overall population. Conclusions: Consistent with the overall population, amivantamab-lazertinib significantly improved OS versus osimertinib among Asian participants with previously untreated EGFR-mutated advanced NSCLC, making it the first regimen to improve survival among Asian patients.